|
π
|
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
14 auth.
O. Chinot,
W. Wick,
W. Mason,
R. Henriksson,
F. Saran,
R. Nishikawa,
A. Carpentier,
K. Hoang-Xuan,
P. Kavan,
D. Cernea,
...
A. Brandes,
M. Hilton,
L. Abrey,
T. Cloughesy
|
11 |
2014 |
11
π
|
|
π
|
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
18 auth.
J. Fayette,
L. Wirth,
C. Oprean,
A. Udrea,
A. Jimeno,
D. Rischin,
C. Nutting,
P. Harari,
T. CsΕszi,
D. Cernea,
...
P. O'brien,
W. Hanley,
A. Kapp,
Maria Anderson,
E. Penuel,
B. McCall,
A. Pirzkall,
J. Vermorken
|
6 |
2016 |
6
π
|
|
π
|
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
21 auth.
A. Brandes,
M. Gil-Gil,
F. Saran,
A. Carpentier,
A. Nowak,
W. Mason,
V. Zagonel,
F. Dubois,
G. Finocchiaro,
G. Fountzilas,
...
D. Cernea,
O. Chinot,
R. Anghel,
F. Ghiringhelli,
P. Beauchesne,
G. Lombardi,
E. Franceschi,
M. Makrutzki,
C. Mpofu,
Hans-Joerg Urban,
J. Pichler
|
5 |
2018 |
5
π
|
|
π
|
Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).
16 auth.
R. Henriksson,
A. Bottomley,
W. Mason,
F. Saran,
W. Wick,
R. Nishikawa,
T. Cloughesy,
Antoine F. Carpentier,
K. Hoang-Xuan,
P. Kavan,
...
D. Cernea,
A. Brandes,
M. Hilton,
Ana Maria Abajo Guijarro,
A. Ravelo,
O. Chinot
|
5 |
2013 |
5
π
|
|
π
|
Functional and molecular characterization of glioblastoma multiforme-derived cancer stem cells.
11 auth.
C. Tomuleasa,
O. SoriΘΔu,
D. Rus-CiucΔ,
H. Ioani,
S. SuΕman,
M. Petrescu,
...
T. Timis,
D. Cernea,
G. Kacso,
A. Irimie,
I. Florian
|
4 |
2010 |
4
π
|
|
π
|
Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme.
12 auth.
C. Tomuleasa,
O. SoriΘΔu,
G. Kacso,
E. Fischer-Fodor,
A. Cocis,
H. Ioani,
...
T. Timis,
M. Petrescu,
D. Cernea,
P. VirΓ‘g,
A. Irimie,
I. Florian
|
4 |
2010 |
4
π
|
|
π
|
Sensitizer drugs for the treatment of temozolomide-resistant glioblastoma.
10 auth.
A. Baritchii,
Anca Jurj,
O. SoriΘΔu,
C. Tomuleasa,
L. Raduly,
Oana Zanoaga,
...
D. Cernea,
C. Braicu,
I. Neagoe,
Ioan Stefan Florian
|
4 |
2016 |
4
π
|
|
π
|
986ORANDOMIZED PHASE II STUDY OF MEHD7945A (MEHD) VS CETUXIMAB (CET) IN >= 2ND-LINE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD & NECK (RMSCCHN) PROGRESSIVE ON/AFTER PLATINUM-BASED CHEMOTHERAPY (PTCT).
18 auth.
J. Fayette,
Lori J. Wirth,
C. Oprean,
R. Hitt,
A. Udrea,
Antonio Jimeno,
Danny Rischin,
Christopher M. Nutting,
P. Harari,
T. CsoΛszi,
...
D. Cernea,
X. Wang,
A. Kapp,
Maria Anderson,
E. Penuel,
B. McCall,
A. Pirzkall,
J. Vermorken
|
3 |
2014 |
3
π
|
|
π
|
Deep-learning magnetic resonance imaging-based automatic segmentation for organs-at-risk in the brain: Accuracy and impact on dose distribution
10 auth.
A. Turcas,
D. Leucuta,
C. Balan,
E. Clementel,
C. Gheara,
A. KacsΓ³,
...
S. Kelly,
Delia Tanasa,
D. Cernea,
P. Achimas-Cadariu
|
3 |
2023 |
3
π
|
|
π
|
FINAL EFFICACY AND SAFETY RESULTS FROM AVAglio, A PHASE III TRIAL OF BEVACIZUMAB (BEV) PLUS TEMOZOLOMIDE (TMZ) ANDRADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA
15 auth.
O. Chinot,
W. Wick,
W. Mason,
R. Henriksson,
F. Saran,
R. Nishikawa,
A. Carpentier,
K. Hoang-Xuan,
P. Kavan,
D. Cernea,
...
A. Brandes,
M. Hilton,
Y. Kerloeguen,
Abajo Guijarro,
T. Cloughsey
|
2 |
2013 |
2
π
|
|
π
|
Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
9 auth.
P. Rusu,
T. Ciuleanu,
D. Cernea,
D. Pelau,
V. GaΓ‘l,
C. Cebotaru,
...
T. Guttman,
N. Todor,
N. Ghilezan
|
2 |
2007 |
2
π
|
